NCT00640432View on ClinicalTrials.gov

Safety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain

PHASE4CompletedINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

October 31, 2004

Conditions
Low Back Pain
Interventions
DRUG

Diclofenac

75 mg oral capsule twice daily for 7 days

DRUG

Celecoxib

400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days

Trial Locations (9)

40420-000

Pfizer Investigational Site, Salvador

74043-110

Pfizer Investigational Site, Goiânia

74075-020

Pfizer Investigational Site, Goiânia

74605-050

Pfizer Investigational Site, Goiânia

86010-010

Pfizer Investigational Site, Londrina

21215-020

Pfizer Investigational Site, Rio de Janeiro

21941-590

Pfizer Investigational Site, Rio de Janeiro

04039-004

Pfizer Investigational Site, São Paulo

08270-070

Pfizer Investigational Site, São Paulo

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00640432 - Safety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain | Biotech Hunter | Biotech Hunter